Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | F2R | P25116 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777748 | 0.90 | MAPT (0.67) | PTGESMAPTLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL3779966 | 0.87 | MAPT (0.54) | PTGESMAPTLMNASMN1; SMN2PPARG | |
| SCHEMBL3774815 | 0.87 | TP53 (0.58) | PTGESMAPTLMNASMN1; SMN2KCNK3 | |
| SCHEMBL3771548 | 0.87 | BCHE (0.68) | PTGESMAPTLMNASMN1; SMN2F2R | |
| SCHEMBL3774731 | 0.87 | MAPT (0.54) | PTGESMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL6724672 | 0.85 | MAPT (0.64) | PTGESMAPTLMNASMN1; SMN2KCNK3 | |
| SCHEMBL3778572 | 0.85 | PPARG (0.73) | PTGESMAPTLMNASMN1; SMN2KCNK3 | |
| SCHEMBL6361733 | 0.84 | CHRNB2 (0.67) | MAPTLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3772291 | 0.84 | MAPT (0.68) | MAPTKCNK3KCNK9PPARGCYP1A2 | |
| SCHEMBL3770493 | 0.84 | KCNK3 (0.60) | PTGESMAPTLMNASMN1; SMN2KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | PTGES 54/4885MAPT 1426/4885LMNA 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.